For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and the formulated version represents a genuine change. These groundbreaking therapies preserve the transthyretin protein, halting its harmful build-up and lessening the burden of the condition . Patients are now experienc